- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Second Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Camcevi | Accord | leuprolide | Accord | Used in men to treat the symptoms of prostate cancer; used in women to treat symptoms of endometriosis or uterine fibroids | 4/4/2022 |
Lyrica | Pfizer | pregabalin | Apotex | Used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury | 4/4/2022 |
Solu-Medrol | Pfizer | methylprednisolone | Dr. Reddy's | Used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders | 4/5/2022 |
Merzee | AbbVie | ethinyl estradiol / norethindrone / ferrous fumarate | Lupin | Used to prevent pregnancy | 4/7/2022 |
Cytotec | Pfizer | misoprostol | ANI | Used to prevent stomach ulcers while you take NSAIDs (such as aspirin, ibuprofen, naproxen), especially if you are at risk for developing ulcers or have a history of ulcers | 4/11/2022 |
Abraxane | Celgene | paclitaxel | Apotex | Used to treat metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas | 4/12/2022 |
Combigan | AbbVie | brimonidine / timolol | Sandoz | Used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension) | 4/14/2022 |
Veltin | Almirall | clindamycin/tretinoin | Solaris | Used to treat acne | 4/14/2022 |
Abraxane | AbbVie | paclitaxel | TWi | Used to treat metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas | 4/18/2022 |
Vimpat | UCB | lacosamide | Breckenridge | Used to prevent and control seizures | 4/19/2022 |
Velcade | Takeda | bortezomib | Baxter | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 4/29/2022 |
Velcade | Takeda | bortezomib | Fresenius Kabi | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 4/29/2022 |
Velcade | Takeda | bortezomib | Apotex | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 5/2/2022 |
Progesterone | Teva | progesterone | Xiromed | Used to prevent endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets | 5/2/2022 |
Velcade | Takeda | bortezomib | Aurobindo | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 5/3/2022 |
Velcade | Takeda | bortezomib | Zydus | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 5/3/2022 |
Velcade | Takeda | bortezomib | Gland | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 5/4/2022 |
Velcade | Takeda | bortezomib | Hospira | Used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma) | 5/4/2022 |
Reyataz | Bristol-Myers Squibb | atazanavir | Hetero / Camber | Used with other HIV medications for infants and children to help control HIV infection | 5/11/2022 |
Esbriet | Genentech | pirfenidone | Teva | Used to treat idiopathic pulmonary fibrosis (IPF) | 5/12/2022 |
Esbriet | Genentech | pirfenidone | Sandoz | Used to treat idiopathic pulmonary fibrosis (IPF) | 5/13/2022 |
Transderm Scop | Baxter | scopolamine | Teva | Used to prevent nausea and vomiting caused by motion sickness or recovery from anesthesia and surgery | 5/13/2022 |
Atripla | Gilead | efavirenz / emtricitabine / tenofovir | Hetero / Camber | Used alone or with other HIV medications to help control HIV infection | 5/16/2022 |
Abreva | Glaxo | docosanol | Cosette | Used to treat "cold sores/fever blisters" (herpes labialis) | 5/24/2022 |
Fosrenol | Takeda | lanthanum | Teva | Used to lower phosphate levels in patients with end stage kidney disease | 5/26/2022 |
Ampyra | Acorda | dalfampridine | Teva | Used to help improve walking in adults with multiple sclerosis (MS) | 6/1/2022 |
Lyvispah | Amneal | baclofen | Amneal | Used to treat muscle stiffness, spasms, and pain from multiple sclerosis | 6/1/2022 |
Pepcid | Johnson & Johnson | famotidine | Hetero / Camber | Used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion) | 6/1/2022 |
Trileptal | Novartis | oxcarbazepine | Hetero / Camber | Used to treat the symptoms of seizures (convulsions) | 6/2/2022 |
CellCept | Roche | mycophenolate | Teva | Used to prevent rejection (antirejection medicine) in people who have received a kidney, heart or liver transplant | 6/3/2022 |
Viibryd | AbbVie | vilazodone | Apotex | Used to treat major depressive disorder (MDD) | 6/6/2022 |
Truvada | Gilead | emtricitabine / tenofovir | Hetero / Camber | Used to treat human immunodeficiency virus (HIV) and hepatitis B virus infection | 6/17/2022 |
Epiduo Forte | Galderma | adapalene | Padagis | Used to treat the symptoms of Acne Vulgaris | 6/21/2022 |
Narcan | Adapt | naloxone | Padagis | Used to treat a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond | 6/21/2022 |
Samsca | Otsuka | tolvaptan | Apotex | Used to treat hyponatremia (low levels of sodium in the blood) in people who have heart failure (condition in which the heart cannot pump enough blood to all parts of the body), syndrome of inappropriate antidiuretic hormone (SIADH; condition in which the body produces too much of a certain natural substance that causes the body to retain water) or other conditions | 6/22/2022 |
Esbriet | Genentech | pirfenidone | Alembic | Used to treat idiopathic pulmonary fibrosis (IPF) | 6/27/2022 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.